Graticule Asia Macro Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Graticule Asia Macro Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-40,950	Closed	-$909K	–	176
2017 Q1	$909K	Buy	40,950 +20,700	+102%	+$444K	0.05%	110
2016 Q4	$382K	Sell	20,250 -11,250	-36%	-$275K	0.05%	95
2016 Q3	$945K	Buy	+31,500	New	+$980K	0.07%	86
2016 Q1	–	Sell	-35,000	Closed	-$1.54M	–	201
2015 Q4	$1.54M	Sell	35,000 -400,205	-92%	-$19.8M	0.25%	145
2015 Q3	$17.7M	Buy	435,205 +308,705	+244%	+$13.5M	2.06%	10
2015 Q2	$6.75M	Buy	+126,500	New	+$6.71M	0.33%	50

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Graticule Asia Macro Advisors's JUNO Position: Q2 2017 in Review

Graticule Asia Macro Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2017, closing a stake of 40,950 shares — an estimated $909K sold.

Graticule Asia Macro Advisors first reported a position in JUNO in Q2 2015 and held it in 6 quarters. The position peaked at $17.7M in Q3 2015. 173 funds tracked by Wall St. Rank hold JUNO as of Q2 2017.

Graticule Asia Macro Advisors reported no remaining Juno Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Graticule Asia Macro Advisors sold 40,950 Juno Therapeutics, Inc. shares in Q2 2017, an estimated $909K.
Graticule Asia Macro Advisors first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 6 quarters.
Graticule Asia Macro Advisors's Juno Therapeutics, Inc. position peaked at $17.7M in Q3 2015.
173 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.